Skip to main content

Table 10 Current ongoing early phase I/II trials with KRAS inhibitors

From: Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

KRAS inhibitors

Drug name

Mechanism of action

Clinical trial (phase)

Study design

Disease

Adagrasib (MRTX849)

KRAS G12C Inhibitor

NCT04330664 (1/2)

Combination with TNO155

KRAS p.G12C mutant solid tumors including NSCLC

Adagrasib (MRTX849)

Irreversible KRAS G12C Inhibitor

NCT04613596 (1/2)

Combination with Pembrolizumab

KRAS p.G12C mutant NSCLC with known PDL1 TPS score

GDC-6036

KRAS G12C Inhibitor

NCT04449874 (1)

Monotherapy

KRAS p.G12C mutant NSCLC

D-1553

KRAS G12C Inhibitor

NCT04585035 (1/2)

Monotherapy and combination with other standard therapies

KRAS p.G12C mutant NSCLC

Rigosertib

RAS-mimetic

NCT04263090 (1/2)

Combination with Nivolumab

KRAS mutant NSCLC with progression on fist line therapy

Sotorasib (AMG 510)

KRAS G12C Inhibitor

NCT03600883 (1/2)

Monotherapy

KRAS p.G12C mutant NSCLC

Sotorasib (AMG 510)

KRAS G12C Inhibitor

NCT04303780 (3)

Monotherapy

KRAS p.G12C mutant NSCLC